ANDA 62863, held by Vitarine. Cephalexin.
As of Nov 14, 2026, ANDA 62863 (Cephalexin), held by Vitarine, was not approved, with 0 approved supplements and 0 published complete response letters.
| CephalexinEQ 250MG BASE · tablet;oral | Cephalexin | Discontinued |
| CephalexinEQ 500MG BASE · tablet;oral | Cephalexin | Discontinued |
| CephalexinEQ 1GM BASE · tablet;oral | Cephalexin | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters